Treatment of hepatitis B e antigen-negative patients

Current Treatment Options in Gastroenterology

Volumn 10, Issue 6, 2007, Pages 474-482

  Hui, Chee Kin ^b   Lau, George K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ENTECAVIR; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; VIRUS DNA;

AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIGEN EXPRESSION; ASIA; AWARENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; LICENCE; LIVER INJURY; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; MUTATIONAL ANALYSIS; OUTCOMES RESEARCH; PREVALENCE; PROGNOSIS; PROMOTER REGION; RELAPSE; REMISSION; REVIEW; UNITED STATES; UNSPECIFIED SIDE EFFECT; VIRUS CARRIER; VIRUS REPLICATION;

EID: 37349002052     PISSN: 10928472     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11938-007-0047-6     Document Type: Review

References (49)

1. Maynard JE, Kane MA, Alter MJ, et al.: Control of hepatitis B by immunization: global perspective. In Viral Hepatitis and Liver Disease. Edited by Zuckerman AJ. New York: Alan R. Liss, Inc.; 1988:967-969.
2. Beasley RP, Hwang LY, Lin CC, et al.: Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet 1981, 318:1129-1133.
3. Wu PC, Fang JW, Lai CL, et al.: Hepatic expression of hepatitis B virus genome in chronic hepatitis B virus infection. Am J Clin Pathol 1996, 105:87-95.
4. Carman WF, Jacyna MR, Hadziyannis S, et al.: Mutation preventing formation of HB e antigen in patients with chronic hepatitis B infection. Lancet 1989, 2:588-591.
5. Chen DS: Hepatitis B virus infection, its sequelae, and prevention in Taiwan. In Neoplasm of the Liver. Edited by Okuda K, Ishak KG. Tokyo: Springer-Verlag; 1987:71-80.
6. Hui CK, Leung N, Yuen ST, et al.: Natural history and disease progression in Chinese chronic hepatitis B patients in the immune-tolerant phase. Hepatology 2007, 46:395-401.
7. Beasley RP, Trepo C, Stevens CE, et al.: The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977, 105:94-98.
8. Hui CK, Cheung WW, Zhang HY, et al.: Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
9. Chen YC, Sheen IS, Chu CM, et al.: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084-1089.
10. Liaw YF, Chu CM, Su IJ, et al.: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983, 84:216-219.
11. Hsu HC, Su IJ, Lai MY, et al.: Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol 1987, 5:45-50.
12. Fattovich G: Natural history and prognosis of hepatitis B. Semin Liv Dis 2003, 23:47-58.
13. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
14. Liaw YF, Tai DI, Chu CM, et al.: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493-496.
15. Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1842-1856.
16. Hui CK, Cheung WW, Zhang HY, et al.: Kinetics and risk of de novo hepatitis B infection in HBsAg negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006, 131:59-68.
17. Brunetto MR, Oliveri F, Coco B, et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263-270.
18. Chu CJ, Hussain M, Lok AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002, 36:1408-1415.
19. Hadziyannis S, Bramou T, Alexopoulou A, et al.: Immunopathogenesis and natural course of anti-HBe- positive chronic hepatitis with replicating B virus. In Viral Hepatitis and Liver Disease. Edited by Hollinger FB, Lemon SM, Margolis HS. Baltimore: Williams & Wilkins; 1992:673-676.
20. Bonino F, Rosina F, Rizzetto M, et al.: Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986, 90:1268-1273.
21. Naoumov NV, Portmann BC, Tedder RS, et al.: Detection of hepatitis B virus antigens in liver tissue. A relation to viral replication and histology in chronic hepatitis B infection. Gastroenterology 1990, 99:1248-1253.
22. Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522-1527.
23. Funk ML, Rosenberg DM, Lok AS: World-wide epidemiology of HBeAg-negative chronic hepatitis Band associated precore and core promoter variants. J Viral Hepatol 2002, 9:52-61.
24. Iloeje UH, Yang HI, Su J, et al.: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
25. Chen CJ, Yang HI, Su J, et al.: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
26. de Franchis R, Hadengue A, Lau G, et al.: EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003, 39(Suppl 1):S3-S25.
27. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45:507-539.
28. Papatheodoridis GV, Hadziyannis SJ: Diagnosis and management of pre-core mutant chronic hepatitis B. J Viral Hepatitis 2001, 8:311-321.
29. Manesis EK, Hadziyannis SJ: Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001, 121:101-109.
30. Janssen HL, Schalm SW, Berk L, et al.: Repeated courses of alpha-interferon for treatment of chronic hepatitis B. J Hepatol 1993, 17(Suppl 3):S47-S51.
31. Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictor factors. Hepatology 1989, 10:761-763.
32. Schiff ER: Treatment algorithms for hepatitis B and C. Gut 1993, 34(Suppl 2):S148-S149.
33. Kao JH, Wu NH, Chen PJ, et al.: Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000, 33:998-1002.
34. Marcellin P, Lau G, Bonino F, et al.: Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004, 351:1206-1217.
35. Schalm SW, de Man RA, Heijtink RA, Niesters HG: New nucleoside analogues for chronic hepatitis B. J Hepatol 1995, 22(Suppl 1):52-56.
36. Dienstag JL, Perillo RP, Schiff ER, et al.: A preliminary trial of lamivudine for chronic hepatitis B infection.N Engl J Med 1995, 333:1704-1705.
37. Tassopoulos NC, Volpes R, Pastore G, et al.: Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999, 29:889-896.
38. Allen MI, Deslauriers M, Andrews CW, et al.: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998, 27:1670-1677.
39. Lok AS, Lai CL, Leung N, et al.: Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003, 125:1714-1722.
40. Melagari M, Scaglioni PP, Wanda JR: Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998, 27:628-633.
41. Ono-Nita SK, Kato M, Shiratori Y, et al.: YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vivo full-length viral DNA transfection. Hepatology 1999, 29:939-945.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003, 348:800-807.
43. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352:2673-2681.
44. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006, 131:1743-1751.
45. Locarnini S, Qi X, Arterburn S, et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil therapy for patients with chronic hepatitis B. J Hepatol 2005, 42(Suppl 1):17.
46. Lai CL, Shouval D, Lok AS, et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006, 354:1011-1020.
47. Colonno RJ, Rose RE, Pokornowski K, et al.: Assessment at three years shows high barrier to resistance is maintained in entecavir treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients [abstract]. Hepatology 2006, 44:229A.
48. Sherman M, Yurdaydin C, Sollano J, et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-2049.
49. Lai CL, Gane E, Chao-Wei H, et al.: Two-year results from the GLOBE Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine vs. lamivudine [abstract]. Hepatology 2006, 44(Suppl):222A.